IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
IOVANCE BIOTHERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amtagvi | $90.72M | $60.22M | $64.90M | $57.48M | $54.07M | $43.57M | $48.71M | $42.04M | $12.82M | – | – | – | 91.3% | +67.8% |
| Proleukin | $8.59M | $11.21M | $21.87M | $9.97M | $5.88M | $5.75M | $24.98M | $16.52M | $18.29M | $715.00K | $482.00K | $469.00K | 8.7% | +46.2% |
| Product | – | – | – | – | – | – | – | – | – | – | – | $500.00K | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $98.97M | $70.47M | $85.49M | $66.40M | $58.61M | $48.52M | $73.19M | $57.82M | $30.03M | $0 | $0 | $0 | 99.7% | +68.9% |
| Non-US | $346.00K | $958.00K | $1.29M | $1.05M | $1.35M | $804.00K | $500.00K | $740.00K | $1.07M | $715.00K | $482.00K | $469.00K | 0.3% | -74.3% |
From the segment and revenue-disaggregation notes of Iovance Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.